Peter Kolchinsky - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Tuesday recap

Top Publishers

  • The Verge AI

    The Verge AI

    21 followers

  • TechCrunch AI

    TechCrunch AI

    19 followers

  • Crunchbase News AI

    Crunchbase News AI

    15 followers

  • TechRadar

    TechRadar

    15 followers

  • Hacker News

    Hacker News

    13 followers

See More →

Top Creators

  • Ryan Allis

    Ryan Allis

    207 followers

  • Elon Musk

    Elon Musk

    79 followers

  • Sam Altman

    Sam Altman

    68 followers

  • Mark Cuban

    Mark Cuban

    56 followers

  • Jack Dorsey

    Jack Dorsey

    39 followers

See More →

Top Companies

  • SaasRise

    SaasRise

    209 followers

  • Anthropic

    Anthropic

    40 followers

  • OpenAI

    OpenAI

    22 followers

  • Hugging Face

    Hugging Face

    15 followers

  • xAI

    xAI

    12 followers

See More →

Top Investors

  • Andreessen Horowitz

    Andreessen Horowitz

    16 followers

  • Y Combinator

    Y Combinator

    15 followers

  • Sequoia Capital

    Sequoia Capital

    12 followers

  • General Catalyst

    General Catalyst

    8 followers

  • A16Z Crypto

    A16Z Crypto

    5 followers

See More →
NewsDealsSocialBlogsVideosPodcasts
Peter Kolchinsky

Peter Kolchinsky

Creator
0 followers

Biotech venture capitalist (RA Capital); scientist and author shaping industry investment strategies.

Combining Modest Therapies Unlocks Big Benefits, Reduces Waste
Social•Mar 28, 2026

Combining Modest Therapies Unlocks Big Benefits, Reduces Waste

Adam, I used to think this way. Then gene therapy & IO worked. IL2 has consumed a lot of hope; but new variations make it hard to quit. Abeta worked. And synergy: combine modest drugs, unlock big benefits. Invest or not, but I now see less waste. I see curiosity.

By Peter Kolchinsky